Applicability and specificity of optical coherence tomography as biomarker of dopaminergic neurodegeneratio

Recruiting

• Conditions: G20; Parkinson disease

• Registration Number: DRKS00031733
• Lead Sponsor: Klinik für Neurologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-24
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Parkinson's syndrome or unclear tremor syndrome (which led to referral to nuclear medicine for FP-CIT SPECT examination).
Signing of the consent form

Exclusion Criteria

- Non-consent or inability to consent to study participation.
- Alcohol/drug abuse (current or history)
- acute psychotic symptoms
- Relevant previous ophthalmologic disease (high-grade visual loss, age-related macular degeneration, glaucoma)
- relevant cognitive impairment (MOCA score < 18)
- severe previous internal disease (e.g. cardiac insufficiency) or orthopedic/rheumatologic previous disease interfering with the planned examinations
- Pregnancy according to self-disclosure

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is whether there is a correlation between the extent of dopaminergic deficit and changes in retinal nerve fiber thickness.<br>

Secondary Outcome Measures

Name	Time	Method
Relationships between striatal dopaminergic neurodegeneration and already established biomarkers of Parkinson's disease (transcranial sonography and olfactory test) as well as possible differences in the collected questionnaires between patients with and without evidence of a dopaminergic deficit.